Open Investment Opportunities

We carefully select every company we support, investing in a maximum of 4 projects a year.
bt_bb_section_bottom_section_coverage_image

We invite investors and their professional advisers

We carefully select every company we support, investing in a maximum of 4 projects a year.

You will have access to Member events where we will showcase new investments, provide the opportunity to meet the management teams and network with like-minded individuals.

There is no joining fee or obligation to invest.
Professional advisors join as Corporate Members and will enjoy the same benefits as Investor Members.
https://www.norcliffe.capital/wp-content/uploads/2020/08/image_illustrations_01.png

Open Investment Opportunities

Afon Technology

Afon Technology Ltd

Sector: MedTech
Total Fundraise: £5 million
Available Investment: £4 million
Status: Open giphy
Tell me more


Afon Technology Limited is developing a non-invasive continual blood glucose monitoring device that delivers results in real-time, enhancing the take up and quality of daily management programs for diabetics.

Norcliffe Capital has raised £4.3 million of investment for Afon Technology enabling the Company to enter the final 12 months of development prior to CE marking.

Recent trials in a world leading diabetes clinical centre in Germany have demonstrated the efficacy of the technology with performances on par to those achieved with commercial invasive devices.

The company is seeking to raise a further £5 million to develop the device ready for CE marking and FDA approval. Afon Technology has a forecasted valuation in 2022 between £50 million and £100 million.

Wifi Securities

Wi-Fi Securities Limited

Sector: Technology and the Internet of Things
Total Fundraise: £3 million
Available Investment: £900,000
Status: Open giphy
Tell me more


Wi-Fi Securities has developed an innovative IP protected system called SpriteGuard™. The SpriteGuard™ system:

  • Protects the security of Wi-Fi systems for users and the Internet of Things.
  • Performance monitors Wi-Fi systems.
  • Provides data for spatial analytics and smart building monitoring.

The SpriteGuard™ system scans and detects all Wi-Fi networks within the surrounding area and all devices connected to them (mobile phone, laptop, tablet, etc.) for illegitimate Wi-Fi networks. If a device accidently connects to a rogue network SpriteGuard™ stops the connection being made and redirects the device to the correct and legitimate Wi-Fi network.

SpriteGuard™ also provides a range of monitoring systems that gather vital data and analytics for the Wi-Fi provider to be used in smart buildings, to enhance security or improve the customer experience.

Norcliffe Capital has raised £1.5 million on behalf of Wi-Fi Securities. The Company is seeking a further £1.5 million to take SpriteGuard™ from its minimal viable product to final product, through CE mark and into the market in 2022.

Aureum Diagnostics

Aureum Diagnostics

Sector: MedTech
Total Fundraise: £3.51 million
Available Investment: £700,000
Status: Open giphy
Tell me more


Medical diagnosis is about to undergo a revolution based on the next generation of cheap, mass manufacturable, electrochemical sensors like those to check blood sugar levels in people with diabetes. Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde and is based on the work of Dr Corrigan and his team.

The team have already demonstrated the ability of their electrochemical platform to detect COVID in 2 minutes and to detect critical markers of sepsis, where a one hour delay in diagnosis can result in a 10% increase in mortality. The platform is ideally suited for rapid diagnosis of many conditions at the point of care and for the rapid diagnosis of COVID in sites like travel hubs, schools, workplaces and at home.

The Company requires £3.51 million for a total investor shareholding of 75.6% of the Company, at a pre-money valuation of £1.13 million to develop two types of readers: highly sensitive impedimetric readers and cheaper amperometric readers which use similar technology to glucose monitoring strips. Potential investor returns are 7x to 15x.

Smi Drug Discovery
SMi Drug Discovery

Sector: MedTech
Total Fundraise: £3.64 million
Available Investment: £800,000
Status: Open giphy
Tell me more


SMi Drug Discovery has developed a transformational, new, optical technology that will have far-reaching benefits in the fields of diagnosis and drug discovery. SMi’s technology is a variant of super resolution microscopy, an area which was the subject of Nobel Prizes in 2014 and 2017. SMi have been awarded a non-dilutive £1.9M UK Innovation grant for the development of their platform for virus diagnosis in large central laboratories.

The system can identify and count individual virus in a sample in 50 milliseconds, with a sensitivity equivalent to the gold standard PCR tests. SMi’s technology complements Aurem’s in that is designed for large central locations.

SMi’s platform’s second application is in speeding up drug discovery where cutting a year off development can save > $100 million. During drug development, scientists need to know how a drug binds to its target, exactly where and for how long. SMi’s technology is revolutionary as it can visualise hundreds of thousands of these interactions whereas current techniques provide only average data. A good analogy is that current techniques are like trying to determine the exact composition of traffic from the noise of vehicles whereas, SMi’s technology photographs and counts every bus, car, lorry and bike.

The Company is raising £3.64 million for 39.6% equity, at a pre-money valuation of £4 million. Potential investor returns are 8x to 16x.

bt_bb_section_bottom_section_coverage_image

COMING SOON

Aureum Diagnostics

Aureum Diagnostics

Medical diagnosis is about to undergo a revolution based on the next generation of cheap, mass manufacturable, electrochemical sensors like those to check blood sugar levels in people with diabetes. Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde and is based on the work of Dr Corrigan and his team.

Read More

Smi Drug Discovery

SMi Drug Discovery

SMi Drug Discovery has developed a transformational, new, optical technology that will have far-reaching benefits in the fields of diagnosis and drug discovery. SMi’s technology is a variant of super resolution microscopy, an area which was the subject of Nobel Prizes in 2014 and 2017. SMi have been awarded a non-dilutive £1.9M UK Innovation grant for the development of their platform for virus diagnosis in large central laboratories.

Read More

bt_bb_section_bottom_section_coverage_image

If you are interested in this investment opportunity then please fill in the form and submit it. We’ll reply to you back as soon as possible.